Quratis, a Kosdaq-listed biotech company, said Friday that it has decided to establish a local corporation in the Philippines to tap into the country's tuberculosis vaccine market.

Quratis has submitted an investigative new drug (IND) application for a phase 2b/3 clinical trial of “QTP101,” a TB vaccine for adolescents and adults, in the Philippines. 

Quratis’s biopharma plant in Osong, North Chungcheong Province
Quratis’s biopharma plant in Osong, North Chungcheong Province

According to Quratis, the Southeast Asian country has a prevalence of 650 TB cases per 100,000 people. Quratis estimates the Philippine TB market to be worth 4.5 trillion won ($3.25 billion) and plans to target it in earnest.

Quratis also emphasized that Philippine President Ferdinand Marcos Jr. has actively implemented TB control policies by creating the Philippine Acceleration Action Plan for Tuberculosis (PAAP-TB), which aims to eliminate TB.

"By establishing a local presence in the Philippines to facilitate QTP101 clinical progress and serve as a hub in Southeast Asia, the region with the highest number of TB patients globally, Quratis will maximize synergies with our network of ASEAN countries, including Indonesia, Thailand, Cambodia, Laos, Myanmar, and Vietnam, and contribute to diversifying our revenue base," a Quratis official said

 

Copyright © KBR Unauthorized reproduction, redistribution prohibited